lower schreef op 17 oktober 2017 10:41:
[...]
Dit is fatale onzin! Het (zeer waarschijnljk) mogen overslaan van Phase3 verantwoord de verdubbeling van de koers.
Kijk maar eens in Tabel 1 van dit artikel
Why The 'Biotech Bubble' Is Economic Nonsense
Oct. 19, 2015
seekingalpha.com/article/3582366-biot...Summary
Many investors consider biotech stocks to be risky bets but few are aware of the global context which brought the recent revaluations of many companies in the sector.
After decades of research, enduring small-cap biotechs are reaching late-stage developments and coming close to market approval of their drugs.
On the other side, big pharma companies which massively divested R&D activities in the last decade are now structurally on the lookout for potential acquisition candidates.
In this context, savvy investors might want to pick biotech stocks which display the right combination of technological maturity and market perspective.
Hence, with a good knowledge of the sector and the right investment horizon, there is still considerable profit to be made in the coming years.